Page 57 - Pharma Sector

Nilesh Gupta to Dilip Shanghvi, most pharma CEOs took a pay cut in FY19

The CEOs' salaries also have taken a brunt. A quick analysis shows that Shanghvi took a whopping 99 per cent pay cut

As price pressure mounts, pharma companies tap analytics to cut costs

Cipla is the first company in the Asia Pacific to upgrade to a cloud-based pharmacovigilance solution

India Inc's expenditure on R&D declines to lowest level in six years

Lower expenditure by pharmaceutical companies may be a key reason for the fall

Sanofi: Strong domestic portfolio keeps Street positive amid pricing pain

Analysts at Elara Capital say the company's portfolio being skewed toward the high-growing chronic products, coupled with its leadership position in basal insulin, gives it an edge over its peers

Dr Reddy's Labs looks to recover from Q1 blues with multiple growth drivers

Steady improvement in the US and India market growth keeps analysts positive

No plans to re-enter domestic formulations in current fiscal: Piramal V-C

Last year, Ajay Piramal, chairman of Piramal Enterprises, had indicated that the firm was exploring a possible re-entry into the domestic formulations market

Purity norms drive nanotech in pharma

A big challenge that drug makers face is the high volume of chemicals which are used and then wasted during the manufacturing process

Caplin Labs gets USFDA nod for injection to prevent excessive blood loss

Caplin Steriles said it has developed and filed 11 ANDAs on its own and with partners, with 5 approvals so far

Cipla eyes Chinese respiratory market through JV with Jiangsu Acebright

The JV will set up a manufacturing facility of respiratory products; the plant is expected to be commissioned in 2020

Sun Pharma bets on nurturing specialty portfolio outlook; stock rises 3.6%

Street is bullish on stabilising US generics sales, upsides from niche portfolio, and inexpensive valuations

Indian pharma firms compliance with USFDA norms improving of late

Pharma industry feels it is unfairly targeted in Katherine Eban's recent book 'Bottle of Lies'

Q4 results preview: Growth recovery for pharma after a muted first half

Lupin and Dr Reddy's lead in terms of growth, Sun Pharma may be impacted by write backs

Combination drug market declines 56% in March as govt clamps down

Govt has banned over 340 FDCs and over 900 are under scrutiny

Anti-infective medicine sales slowing down: Pharmaceutical industry

Focus on chronic therapies and ban on some combination drugs among reasons

This pharma entrepreneur became a billionaire by pushing opiods on patients

The sales strategy was based on an 'eat-what-you-kill philosophy,' a former chief executive officer of the firm said. 'When you sell a lot, you make a lot.'

Booster dose for pharma as Govt okays refund on foreign plant inspection

Commerce Ministry raises cap to Rs 2 crore a year per drug exporter from Rs 50 lakh under MAI scheme; 50% of costs incurred towards statutory compliance to be borne by firm

Acute therapy segments pull down domestic pharma sales growth to 6% in Nov

While Indian companies grew 6.2 per cent for the month, multinational firms grew slightly faster at 6.8 per cent for the same period

Pharma sector likely to post higher Q2 margins on weak rupee: India Ratings

It expects that the positive currency impact to continue and the rupee to average Rs 69.79 per US dollar in FY19, a depreciation of 8.3 per cent

Dr Reddy's sells Hyderabad API unit to Neopharma JV in lump sum deal

Therapiva Private Limited is a joint venture between Omnicare Drugs India Private Limited, a subsidiary of Neopharma LLC, Abu Dhabi and Laxai Life Sciences Private Limited

Pharma sector back in focus; outlook positive but bets likely to be risky

Things are further improving for companies focussed on the US. Many large generic US players are moving out of certain drugs, which creates opportunities for the Indian players